Spherix Incorporated was launched in 1967 as a scientific research company. The company now leverages its scientific and technical expertise and experience through its two subsidiaries—Biospherics Incorporated and Spherix Consulting, Inc. Biospherics just announced new results of preclinical studies of SPX-106T, a new compound recently in-licensed. Biospherics has also completed a global Phase 3 clinical trial investigating the use of D-Tagatose, a stereoisomer of fructose already approved as a sugar substitute, as a treatment for glycemic control in patients with Type 2 diabetes. Spherix Consulting provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides.
As its primary goals, Spherix is seeking to successfully commercialize SPX-106T worldwide, D-Tagatose in the U.S. and other markets, to advance its pre-clinical pipeline, and to promote its consulting practice as the premier product regulatory approval and scientific advisory service.
The Company’s mission is to create and grow shareholder value through innovations that benefit its clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to food, consumer product and pharmaceutical companies. Through its two subsidiaries, Biospherics and Spherix Health Sciences Consulting, Spherix strives to better the human condition.
- The Biospherics mission is to be an innovative company developing and commercializing proprietary health, drug, and medical products and processes.
- The Spherix Consulting mission is to provide the necessary strategic, regulatory, and scientific support to our clients for the purpose of securing their successful market position by assuring the safety, regulatory compliance/approval and benefit of their products.
Headquartered in Bethesda, Maryland, Spherix common stock trades on the NASDAQ under the symbol SPEX.